Vivos Therapeutics annual current ratio
2019
2020
2021
2022
2023
2024
2025
Vivos Therapeutics Current Ratio Growth & History (VVOS)
Vivos Therapeutics's current ratio was 0.24 for fiscal 2025.
View full Vivos Therapeutics company overviewVivos Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.24 | −1.26 | −83.84% |
| 2024 | 2024-12-31 | 1.50 | 1.16 | +344.63% |
| 2023 | 2023-12-31 | 0.34 | −0.46 | −57.59% |
| 2022 | 2022-12-31 | 0.80 | −2.84 | −78.12% |
| 2021 | 2021-12-31 | 3.64 | 1.04 | +39.90% |
| 2020 | 2020-12-31 | 2.60 | 2.38 | +1092.05% |
| 2019 | 2019-12-31 | 0.22 | — | — |
Vivos Therapeutics quarterly current ratio
Q4.19
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.21 | −0.84 | −80.27% |
| Q1 2026 | 2026-03-31 | 0.27 | −0.50 | −64.99% |
| Q4 2025 | 2025-12-31 | 0.24 | −1.26 | −83.84% |
| Q3 2025 | 2025-09-30 | 0.78 | −0.67 | −46.10% |
| Q2 2025 | 2025-06-30 | 1.05 | −0.13 | −11.39% |
| Q1 2025 | 2025-03-31 | 0.77 | 0.32 | +71.48% |
| Q4 2024 | 2024-12-31 | 1.50 | 1.16 | +344.63% |
| Q3 2024 | 2024-09-30 | 1.44 | 1.17 | +421.16% |
| Q2 2024 | 2024-06-30 | 1.18 | 0.55 | +86.75% |
| Q1 2024 | 2024-03-31 | 0.45 | −0.65 | −59.04% |
| Q4 2023 | 2023-12-31 | 0.34 | −0.46 | −57.59% |
| Q3 2023 | 2023-09-30 | 0.28 | −1.35 | −82.97% |
| Q2 2023 | 2023-06-30 | 0.63 | −1.68 | −72.69% |
| Q1 2023 | 2023-03-31 | 1.09 | −2.34 | −68.18% |
| Q4 2022 | 2022-12-31 | 0.80 | −2.84 | −78.12% |
| Q3 2022 | 2022-09-30 | 1.63 | −2.53 | −60.83% |
| Q2 2022 | 2022-06-30 | 2.32 | −1.91 | −45.20% |
| Q1 2022 | 2022-03-31 | 3.43 | 1.14 | +49.66% |
| Q4 2021 | 2021-12-31 | 3.64 | 1.04 | +39.90% |
| Q3 2021 | 2021-09-30 | 4.15 | — | — |
| Q2 2021 | 2021-06-30 | 4.23 | — | — |
| Q1 2021 | 2021-03-31 | 2.29 | — | — |
| Q4 2020 | 2020-12-31 | 2.60 | 2.38 | +1092.05% |
| Q4 2019 | 2019-12-31 | 0.22 | — | — |
Vivos Therapeutics current ratio trends
Over the last five fiscal years, Vivos Therapeutics's current ratio decreased from 2.60 to 0.24, a change of −2.36. The latest reported quarter, Q2 2026, shows 0.21.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vivos Therapeutics source filings ↗